市場調査レポート

商品コード

1179679

知覚障害治療市場：疾患タイプ別、治療法別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Paresthesia Treatment Market By Disease Type, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年09月01日 | 発行: Allied Market Research

| ページ情報: 英文 328 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 6,090 954,668円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,630 1,039,318円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 10,500 1,645,980円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の知覚障害治療市場は、2021年に53億7,628万米ドルとなり、2022年から2031年にかけてCAGR3.8%を記録し、2031年には79億米ドルに達すると予測されます。

知覚障害は、手、腕、脚、足などの四肢に最も多く発生するしびれや焼けつくような感覚です。手や腕、足など四肢に多くみられ、体の他の部位に起こることもあります。足や脚に長時間座ったときに起こる「ピンと張った感じ」と同じです。腕や足の神経が何らかの圧力下にあるときに起こります。圧力がなくなれば、不快感はなくなります。人によっては、より深刻な神経の損傷や状態の兆候である慢性的な知覚障害を持つ場合があります。知覚障害の原因としては、脳卒中、多発性硬化症、脊髄や脳の腫瘍、ビタミンDやその他のビタミンの高値、糖尿病、線維筋痛症、高血圧、感染、神経損傷、神経の圧迫や挟み込みなどが挙げられます。知覚障害の症状には、ピリピリ感や「ピン・アンド・ニードル」感覚、痛みや灼熱感、患部のしびれや感覚低下、患部が「眠ってしまった」感覚、チクチク感やかゆみ、皮膚の熱さや冷たさなどが含まれます。

知覚障害治療の世界市場は、がんなどの疾患の有病率の上昇、老年人口の急増、食品中の適切な栄養素の不足により、予測期間中に大きな市場成長を示すと予想されます。さらに、国民の知覚障害の増加、貧しいライフスタイル、医療費の増加も市場成長に大きく寄与しています。しかし、治療に関連する医薬品の効果が低いことや、医薬品の承認に関する当局の厳しい規制規則が、市場の成長にマイナスの影響を与えています。逆に、より良い治療のための研究開発への投資の急増は、市場成長のための有利な機会を提供しています。

概要
- 市場規模および予測
急性感覚鈍麻
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別分析
- 急性知覚障害の治療市場：年齢層別
慢性感覚障害
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
- 慢性感覚異常の治療市場：年齢層別

第5章知覚障害治療市場：治療法別

概要
- 市場規模・予測
免疫抑制剤
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
抗けいれん剤
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
局所用クリーム
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
抗ウイルス剤
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第6章知覚障害治療市場：流通チャネル別

概要
- 市場規模・予測
病院薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
小売薬局
- 主要な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
オンライン薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章知覚障害治療市場：地域別

概要
- 市場規模・予測
北米
- 主な動向と機会
- 北米市場規模・予測：疾患タイプ別
- 北米市場規模・予測：治療法別
- 北米市場規模・予測：流通チャネル別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主な動向と機会
- 欧州市場規模・予測：疾患タイプ別
- 欧州市場規模・予測：治療法別
- 欧州市場規模・予測：流通チャネル別
- 欧州市場規模・予測：国別
  - フランス
  - ドイツ
  - 英国
  - イタリア
  - スペイン
  - その他欧州
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：疾患タイプ別
- アジア太平洋地域の市場規模・予測：治療法別
- アジア太平洋地域の市場規模・予測：流通チャネル別
- アジア太平洋地域の市場規模・予測：国別
  - 日本
  - 中国
  - インド
  - オーストラリア
  - 韓国
  - 台湾
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：疾患タイプ別
- LAMEAの市場規模・予測：治療法別
- LAMEAの市場規模・予測：流通チャネル別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - トルコ
  - ベネズエラ
  - サウジアラビア
  - 南アフリカ
  - その他のLAMEA

第8章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第9章企業プロファイル

Abbott Laboratories
AbbVie Inc.
Baxter International Inc.
Bio-Medical Research Ltd.
Boston Scientific Corporation
Cipla Ltd.
Cyberonics, Inc.
EnteroMedics Inc.
GlaxoSmithKline plc.
Glenmark
Medtronic
Merck
Nevro Corp.
Omron Healthcare, Inc.
Pfizer
Stimwave LLC
Stryker Corp.

図表

LIST OF TABLES

TABLE 1. GLOBAL PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 2. PARESTHESIA TREATMENT MARKET SIZE, FOR ACUTE PARESTHESIA, BY REGION, 2021-2031 ($MILLION)
TABLE 3. PARESTHESIA TREATMENT MARKET FOR ACUTE PARESTHESIA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. GLOBAL ACUTE PARESTHESIA PARESTHESIA TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 5. PARESTHESIA TREATMENT MARKET SIZE, FOR CHRONIC PARESTHESIA, BY REGION, 2021-2031 ($MILLION)
TABLE 6. PARESTHESIA TREATMENT MARKET FOR CHRONIC PARESTHESIA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 7. GLOBAL CHRONIC PARESTHESIA PARESTHESIA TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 8. GLOBAL PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 9. PARESTHESIA TREATMENT MARKET SIZE, FOR IMMUNOSUPPRESSANT, BY REGION, 2021-2031 ($MILLION)
TABLE 10. PARESTHESIA TREATMENT MARKET FOR IMMUNOSUPPRESSANT, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. PARESTHESIA TREATMENT MARKET SIZE, FOR ANTICONVULSANTS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. PARESTHESIA TREATMENT MARKET FOR ANTICONVULSANTS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. PARESTHESIA TREATMENT MARKET SIZE, FOR TOPICAL CREAMS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. PARESTHESIA TREATMENT MARKET FOR TOPICAL CREAMS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. PARESTHESIA TREATMENT MARKET SIZE, FOR ANTIVIRALS, BY REGION, 2021-2031 ($MILLION)
TABLE 16. PARESTHESIA TREATMENT MARKET FOR ANTIVIRALS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. PARESTHESIA TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 18. PARESTHESIA TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. GLOBAL PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 20. PARESTHESIA TREATMENT MARKET SIZE, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
TABLE 21. PARESTHESIA TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. PARESTHESIA TREATMENT MARKET SIZE, FOR RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
TABLE 23. PARESTHESIA TREATMENT MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. PARESTHESIA TREATMENT MARKET SIZE, FOR ONLINE PHARMACY, BY REGION, 2021-2031 ($MILLION)
TABLE 25. PARESTHESIA TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. PARESTHESIA TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA PARESTHESIA TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. U.S. PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 32. U.S. PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 33. U.S. PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. CANADA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 35. CANADA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 36. CANADA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 37. MEXICO PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 38. MEXICO PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 39. MEXICO PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 40. EUROPE PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 41. EUROPE PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 42. EUROPE PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 43. EUROPE PARESTHESIA TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 44. FRANCE PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 45. FRANCE PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 46. FRANCE PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 47. GERMANY PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 48. GERMANY PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 49. GERMANY PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 50. UK PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 51. UK PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 52. UK PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 53. ITALY PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 54. ITALY PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 55. ITALY PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 56. SPAIN PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 57. SPAIN PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 58. SPAIN PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 59. REST OF EUROPE PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 60. REST OF EUROPE PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 62. ASIA-PACIFIC PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC PARESTHESIA TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 66. JAPAN PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 67. JAPAN PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 68. JAPAN PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 69. CHINA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 70. CHINA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 71. CHINA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 72. INDIA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 73. INDIA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 74. INDIA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. AUSTRALIA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 76. AUSTRALIA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 77. AUSTRALIA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. SOUTH KOREA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 79. SOUTH KOREA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 80. SOUTH KOREA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. TAIWAN PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 82. TAIWAN PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 83. TAIWAN PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. REST OF ASIA PACIFIC PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 85. REST OF ASIA PACIFIC PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 86. REST OF ASIA PACIFIC PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. LAMEA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 88. LAMEA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 89. LAMEA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 90. LAMEA PARESTHESIA TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 91. BRAZIL PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 92. BRAZIL PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 93. BRAZIL PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 94. TURKEY PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 95. TURKEY PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 96. TURKEY PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 97. VENEZUELA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 98. VENEZUELA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 99. VENEZUELA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 100. SAUDI ARABIA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 101. SAUDI ARABIA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 102. SAUDI ARABIA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 103. SOUTH AFRICA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 104. SOUTH AFRICA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 105. SOUTH AFRICA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 106. REST OF LAMEA PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 107. REST OF LAMEA PARESTHESIA TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 108. REST OF LAMEA PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 109.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 110.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 111.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 112.ABBOTT LABORATORIES: NET SALES,
TABLE 113.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 114.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 115.ABBVIE INC.: OPERATING SEGMENTS
TABLE 116.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 117.ABBVIE INC.: NET SALES,
TABLE 118.ABBVIE INC.: KEY STRATERGIES
TABLE 119.BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
TABLE 120.BAXTER INTERNATIONAL INC.: OPERATING SEGMENTS
TABLE 121.BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
TABLE 122.BAXTER INTERNATIONAL INC.: NET SALES,
TABLE 123.BAXTER INTERNATIONAL INC.: KEY STRATERGIES
TABLE 124.BIO-MEDICAL RESEARCH LTD.: COMPANY SNAPSHOT
TABLE 125.BIO-MEDICAL RESEARCH LTD.: OPERATING SEGMENTS
TABLE 126.BIO-MEDICAL RESEARCH LTD.: PRODUCT PORTFOLIO
TABLE 127.BIO-MEDICAL RESEARCH LTD.: NET SALES,
TABLE 128.BIO-MEDICAL RESEARCH LTD.: KEY STRATERGIES
TABLE 129.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 130.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
TABLE 131.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
TABLE 132.BOSTON SCIENTIFIC CORPORATION: NET SALES,
TABLE 133.BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
TABLE 134.CIPLA LTD.: COMPANY SNAPSHOT
TABLE 135.CIPLA LTD.: OPERATING SEGMENTS
TABLE 136.CIPLA LTD.: PRODUCT PORTFOLIO
TABLE 137.CIPLA LTD.: NET SALES,
TABLE 138.CIPLA LTD.: KEY STRATERGIES
TABLE 139.CYBERONICS, INC.: COMPANY SNAPSHOT
TABLE 140.CYBERONICS, INC.: OPERATING SEGMENTS
TABLE 141.CYBERONICS, INC.: PRODUCT PORTFOLIO
TABLE 142.CYBERONICS, INC.: NET SALES,
TABLE 143.CYBERONICS, INC.: KEY STRATERGIES
TABLE 144.ENTEROMEDICS INC.: COMPANY SNAPSHOT
TABLE 145.ENTEROMEDICS INC.: OPERATING SEGMENTS
TABLE 146.ENTEROMEDICS INC.: PRODUCT PORTFOLIO
TABLE 147.ENTEROMEDICS INC.: NET SALES,
TABLE 148.ENTEROMEDICS INC.: KEY STRATERGIES
TABLE 149.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 150.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 151.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 152.GLAXOSMITHKLINE PLC.: NET SALES,
TABLE 153.GLAXOSMITHKLINE PLC.: KEY STRATERGIES
TABLE 154.GLENMARK: COMPANY SNAPSHOT
TABLE 155.GLENMARK: OPERATING SEGMENTS
TABLE 156.GLENMARK: PRODUCT PORTFOLIO
TABLE 157.GLENMARK: NET SALES,
TABLE 158.GLENMARK: KEY STRATERGIES
TABLE 159.MEDTRONIC: COMPANY SNAPSHOT
TABLE 160.MEDTRONIC: OPERATING SEGMENTS
TABLE 161.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 162.MEDTRONIC: NET SALES,
TABLE 163.MEDTRONIC: KEY STRATERGIES
TABLE 164.MERCK: COMPANY SNAPSHOT
TABLE 165.MERCK: OPERATING SEGMENTS
TABLE 166.MERCK: PRODUCT PORTFOLIO
TABLE 167.MERCK: NET SALES,
TABLE 168.MERCK: KEY STRATERGIES
TABLE 169.NEVRO CORP.: COMPANY SNAPSHOT
TABLE 170.NEVRO CORP.: OPERATING SEGMENTS
TABLE 171.NEVRO CORP.: PRODUCT PORTFOLIO
TABLE 172.NEVRO CORP.: NET SALES,
TABLE 173.NEVRO CORP.: KEY STRATERGIES
TABLE 174.OMRON HEALTHCARE, INC.: COMPANY SNAPSHOT
TABLE 175.OMRON HEALTHCARE, INC.: OPERATING SEGMENTS
TABLE 176.OMRON HEALTHCARE, INC.: PRODUCT PORTFOLIO
TABLE 177.OMRON HEALTHCARE, INC.: NET SALES,
TABLE 178.OMRON HEALTHCARE, INC.: KEY STRATERGIES
TABLE 179.PFIZER: COMPANY SNAPSHOT
TABLE 180.PFIZER: OPERATING SEGMENTS
TABLE 181.PFIZER: PRODUCT PORTFOLIO
TABLE 182.PFIZER: NET SALES,
TABLE 183.PFIZER: KEY STRATERGIES
TABLE 184.STIMWAVE LLC: COMPANY SNAPSHOT
TABLE 185.STIMWAVE LLC: OPERATING SEGMENTS
TABLE 186.STIMWAVE LLC: PRODUCT PORTFOLIO
TABLE 187.STIMWAVE LLC: NET SALES,
TABLE 188.STIMWAVE LLC: KEY STRATERGIES
TABLE 189.STRYKER CORP.: COMPANY SNAPSHOT
TABLE 190.STRYKER CORP.: OPERATING SEGMENTS
TABLE 191.STRYKER CORP.: PRODUCT PORTFOLIO
TABLE 192.STRYKER CORP.: NET SALES,
TABLE 193.STRYKER CORP.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.PARESTHESIA TREATMENT MARKET SEGMENTATION
FIGURE 2.PARESTHESIA TREATMENT MARKET,2021-2031
FIGURE 3.PARESTHESIA TREATMENT MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.PARESTHESIA TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.PARESTHESIA TREATMENT MARKET,BY DISEASE TYPE,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ACUTE PARESTHESIA PARESTHESIA TREATMENT MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CHRONIC PARESTHESIA PARESTHESIA TREATMENT MARKET,2021-2031(%)
FIGURE 15.PARESTHESIA TREATMENT MARKET,BY TREATMENT,2021(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF IMMUNOSUPPRESSANT PARESTHESIA TREATMENT MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANTICONVULSANTS PARESTHESIA TREATMENT MARKET,2021-2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF TOPICAL CREAMS PARESTHESIA TREATMENT MARKET,2021-2031(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ANTIVIRALS PARESTHESIA TREATMENT MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS PARESTHESIA TREATMENT MARKET,2021-2031(%)
FIGURE 21.PARESTHESIA TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY PARESTHESIA TREATMENT MARKET,2021-2031(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY PARESTHESIA TREATMENT MARKET,2021-2031(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACY PARESTHESIA TREATMENT MARKET,2021-2031(%)
FIGURE 25.PARESTHESIA TREATMENT MARKET BY REGION,2021
FIGURE 26.U.S. PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 27.CANADA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 28.MEXICO PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 29.FRANCE PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 30.GERMANY PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 31.UK PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 32.ITALY PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 33.SPAIN PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 34.REST OF EUROPE PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 35.JAPAN PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 36.CHINA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 37.INDIA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 38.AUSTRALIA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 39.SOUTH KOREA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 40.TAIWAN PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 41.REST OF ASIA PACIFIC PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 42.BRAZIL PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 43.TURKEY PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 44.VENEZUELA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 45.SAUDI ARABIA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 46.SOUTH AFRICA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 47.REST OF LAMEA PARESTHESIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 52.COMPETITIVE DASHBOARD
FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 54.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
FIGURE 55.ABBVIE INC..: NET SALES ,($MILLION)
FIGURE 56.BAXTER INTERNATIONAL INC..: NET SALES ,($MILLION)
FIGURE 57.BIO-MEDICAL RESEARCH LTD..: NET SALES ,($MILLION)
FIGURE 58.BOSTON SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
FIGURE 59.CIPLA LTD..: NET SALES ,($MILLION)
FIGURE 60.CYBERONICS, INC..: NET SALES ,($MILLION)
FIGURE 61.ENTEROMEDICS INC..: NET SALES ,($MILLION)
FIGURE 62.GLAXOSMITHKLINE PLC..: NET SALES ,($MILLION)
FIGURE 63.GLENMARK.: NET SALES ,($MILLION)
FIGURE 64.MEDTRONIC.: NET SALES ,($MILLION)
FIGURE 65.MERCK.: NET SALES ,($MILLION)
FIGURE 66.NEVRO CORP..: NET SALES ,($MILLION)
FIGURE 67.OMRON HEALTHCARE, INC..: NET SALES ,($MILLION)
FIGURE 68.PFIZER.: NET SALES ,($MILLION)
FIGURE 69.STIMWAVE LLC.: NET SALES ,($MILLION)
FIGURE 70.STRYKER CORP..: NET SALES ,($MILLION)

Product Code: A17080

The global paresthesia treatment market was valued at $5,376.28 million in 2021, and is projected to reach $7,900.0 million by 2031, registering a CAGR of 3.8% from 2022 to 2031.

Paresthesia is numbness and a burning feeling that occurs most often in the extremities, such as the hands, arms, legs, or feet. It can occur elsewhere in the body as well. It is the same "pins and needles" feeling that happens when someone sits on their leg or foot for too long. It is caused when the nerves of arms and legs are under any kind of pressure. The discomfort goes away, once that pressure is relieved. Some people may have chronic paresthesia, which could be a sign of a more serious nerve injury or condition. Some of the causes of paresthesia include stroke, multiple sclerosis, tumor in the spinal cord or brain, high levels of vitamin D or other vitamins, diabetes, fibromyalgia, high blood pressure, infection, nerve injury, and compressed or pinched nerve. The symptoms of paresthesia include tingling or a "pins and needles" sensation, aching or burning pain, numbness or poor feeling in the affected area, a feeling that the affected area has "fallen asleep", prickling or itching feeling, and hot or cold skin.

The global paresthesia treatment market is anticipated to show significant market growth during the forecast period, owing to rise in the prevalence of disease such as cancer, surge in geriatric population, and lack of proper nutrients in the food. Furthermore, increase in prevalence of paresthesia among the population, poor lifestyle, and surge in healthcare expenditure considerably contribute toward the market growth. However, low effectiveness of medicines associated with the treatment and stringent regulatory rules of the authority for the approvals of the medicines negatively impact the market growth. Conversely, the surge in investments in the research and developments (R&Ds) for better treatment offers lucrative opportunities for the growth of the market.

The paresthesia treatment market is segmented on the basis of disease type, treatment, distribution channel, and region. By disease type, the market is bifurcated into acute paresthesia and chronic paresthesia. Furthermore, the acute paresthesia is sub-classified as pediatric and adult. The chronic paresthesia segment is sub-classified as pediatric and adult. By treatment, the market is fragmented into immunosuppressant, anticonvulsants, topical creams, antivirals, and others. By distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Taiwan and Rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Venezuela, South Africa, Saudi Arabia, and Rest of LAMEA).

The major companies profiled in the report include: Abbott Laboratories, AbbVie Inc., Baxter International Inc., Bio-Medical Research Ltd., Boston Scientific Corporation, Cipla Ltd., Cyberonics, Inc., GlaxoSmithKline plc., Glenmark Pharmaceuticals, Medtronic plc, Merck KGaA, NeuroBo Pharmaceuticals, Inc., Nevro Corporation, Omron Healthcare, Inc. , Pfizer Inc., Reshape Lifesciences Inc., and Stimwave, LLC.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the paresthesia treatment market analysis from 2021 to 2031 to identify the prevailing paresthesia treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the paresthesia treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global paresthesia treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

Acute Paresthesia
- Age Group
- Adult
- Geriatric
Chronic Paresthesia
- Age Group
- Adult
- Geriatric

By Treatment

Immunosuppressant
Anticonvulsants
Topical Creams
Antivirals
Others

By Distribution Channel

Online Pharmacy
Hospital Pharmacy
Retail Pharmacy

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Spain
- Rest of Europe
- France
- Germany
- UK
- Italy
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Taiwan
- Rest Of Asia Pacific
LAMEA
- Brazil
- Turkey
- Venezuela
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbott Laboratories
- AbbVie Inc.
- Baxter International Inc.
- Bio-Medical Research Ltd.
- Boston Scientific Corporation
- Cipla Ltd.
- Cyberonics, Inc.
- EnteroMedics Inc.
- GlaxoSmithKline plc.
- Glenmark
- Medtronic
- Merck
- Nevro Corp.
- Omron Healthcare, Inc.
- Pfizer
- Stimwave LLC
- Stryker Corp.

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Acute Paresthesia
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.2.4 Acute Paresthesia Paresthesia Treatment Market by Age Group
4.3 Chronic Paresthesia
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 Chronic Paresthesia Paresthesia Treatment Market by Age Group

CHAPTER 5: PARESTHESIA TREATMENT MARKET, BY TREATMENT

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Immunosuppressant
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Anticonvulsants
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Topical Creams
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
5.5 Antivirals
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
5.6 Others
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country

CHAPTER 6: PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospital Pharmacy
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Retail Pharmacy
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Online Pharmacy
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: PARESTHESIA TREATMENT MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Disease Type
- 7.2.3 North America Market size and forecast, by Treatment
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Disease Type
  - 7.2.5.1.2 Market size and forecast, by Treatment
  - 7.2.5.1.3 Market size and forecast, by Distribution Channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Disease Type
  - 7.2.5.2.2 Market size and forecast, by Treatment
  - 7.2.5.2.3 Market size and forecast, by Distribution Channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Disease Type
  - 7.2.5.3.2 Market size and forecast, by Treatment
  - 7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Disease Type
- 7.3.3 Europe Market size and forecast, by Treatment
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 France
  - 7.3.5.1.1 Market size and forecast, by Disease Type
  - 7.3.5.1.2 Market size and forecast, by Treatment
  - 7.3.5.1.3 Market size and forecast, by Distribution Channel
  - 7.3.5.2 Germany
  - 7.3.5.2.1 Market size and forecast, by Disease Type
  - 7.3.5.2.2 Market size and forecast, by Treatment
  - 7.3.5.2.3 Market size and forecast, by Distribution Channel
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Disease Type
  - 7.3.5.3.2 Market size and forecast, by Treatment
  - 7.3.5.3.3 Market size and forecast, by Distribution Channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Disease Type
  - 7.3.5.4.2 Market size and forecast, by Treatment
  - 7.3.5.4.3 Market size and forecast, by Distribution Channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Disease Type
  - 7.3.5.5.2 Market size and forecast, by Treatment
  - 7.3.5.5.3 Market size and forecast, by Distribution Channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Disease Type
  - 7.3.5.6.2 Market size and forecast, by Treatment
  - 7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Disease Type
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Disease Type
  - 7.4.5.1.2 Market size and forecast, by Treatment
  - 7.4.5.1.3 Market size and forecast, by Distribution Channel
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Disease Type
  - 7.4.5.2.2 Market size and forecast, by Treatment
  - 7.4.5.2.3 Market size and forecast, by Distribution Channel
  - 7.4.5.3 India
  - 7.4.5.3.1 Market size and forecast, by Disease Type
  - 7.4.5.3.2 Market size and forecast, by Treatment
  - 7.4.5.3.3 Market size and forecast, by Distribution Channel
  - 7.4.5.4 Australia
  - 7.4.5.4.1 Market size and forecast, by Disease Type
  - 7.4.5.4.2 Market size and forecast, by Treatment
  - 7.4.5.4.3 Market size and forecast, by Distribution Channel
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Disease Type
  - 7.4.5.5.2 Market size and forecast, by Treatment
  - 7.4.5.5.3 Market size and forecast, by Distribution Channel
  - 7.4.5.6 Taiwan
  - 7.4.5.6.1 Market size and forecast, by Disease Type
  - 7.4.5.6.2 Market size and forecast, by Treatment
  - 7.4.5.6.3 Market size and forecast, by Distribution Channel
  - 7.4.5.7 Rest Of Asia Pacific
  - 7.4.5.7.1 Market size and forecast, by Disease Type
  - 7.4.5.7.2 Market size and forecast, by Treatment
  - 7.4.5.7.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Disease Type
- 7.5.3 LAMEA Market size and forecast, by Treatment
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Disease Type
  - 7.5.5.1.2 Market size and forecast, by Treatment
  - 7.5.5.1.3 Market size and forecast, by Distribution Channel
  - 7.5.5.2 Turkey
  - 7.5.5.2.1 Market size and forecast, by Disease Type
  - 7.5.5.2.2 Market size and forecast, by Treatment
  - 7.5.5.2.3 Market size and forecast, by Distribution Channel
  - 7.5.5.3 Venezuela
  - 7.5.5.3.1 Market size and forecast, by Disease Type
  - 7.5.5.3.2 Market size and forecast, by Treatment
  - 7.5.5.3.3 Market size and forecast, by Distribution Channel
  - 7.5.5.4 Saudi Arabia
  - 7.5.5.4.1 Market size and forecast, by Disease Type
  - 7.5.5.4.2 Market size and forecast, by Treatment
  - 7.5.5.4.3 Market size and forecast, by Distribution Channel
  - 7.5.5.5 South Africa
  - 7.5.5.5.1 Market size and forecast, by Disease Type
  - 7.5.5.5.2 Market size and forecast, by Treatment
  - 7.5.5.5.3 Market size and forecast, by Distribution Channel
  - 7.5.5.6 Rest of LAMEA
  - 7.5.5.6.1 Market size and forecast, by Disease Type
  - 7.5.5.6.2 Market size and forecast, by Treatment
  - 7.5.5.6.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Abbott Laboratories
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 AbbVie Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Baxter International Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Bio-Medical Research Ltd.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Boston Scientific Corporation
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Cipla Ltd.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Cyberonics, Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 EnteroMedics Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 GlaxoSmithKline plc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Glenmark
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
9.11 Medtronic
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
9.12 Merck
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
9.13 Nevro Corp.
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
9.14 Omron Healthcare, Inc.
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
9.15 Pfizer
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
9.16 Stimwave LLC
- 9.16.1 Company overview
- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
9.17 Stryker Corp.
- 9.17.1 Company overview
- 9.17.2 Company snapshot
- 9.17.3 Operating business segments
- 9.17.4 Product portfolio
- 9.17.5 Business performance
- 9.17.6 Key strategic moves and developments

知覚障害治療市場：疾患タイプ別、治療法別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Paresthesia Treatment Market By Disease Type, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章知覚障害治療市場：疾患タイプ別

第5章知覚障害治療市場：治療法別

第6章知覚障害治療市場：流通チャネル別

第7章知覚障害治療市場：地域別

第8章企業情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE

CHAPTER 5: PARESTHESIA TREATMENT MARKET, BY TREATMENT

CHAPTER 6: PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: PARESTHESIA TREATMENT MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

知覚障害治療市場：疾患タイプ別、治療法別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Paresthesia Treatment Market By Disease Type, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 知覚障害治療市場：疾患タイプ別

第5章 知覚障害治療市場：治療法別

第6章 知覚障害治療市場：流通チャネル別

第7章 知覚障害治療市場：地域別

第8章 企業情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE

CHAPTER 5: PARESTHESIA TREATMENT MARKET, BY TREATMENT

CHAPTER 6: PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: PARESTHESIA TREATMENT MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章知覚障害治療市場：疾患タイプ別

第5章知覚障害治療市場：治療法別

第6章知覚障害治療市場：流通チャネル別

第7章知覚障害治療市場：地域別

第8章企業情勢

第9章企業プロファイル